In a report released yesterday, Lance Wilkes from Bernstein maintained a Buy rating on Centene (CNC – Research Report), with a price target of $100.00. The company’s shares closed yesterday at $78.32.
According to TipRanks, Wilkes is a 4-star analyst with an average return of 15.2% and a 69.44% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Cigna, HCA Healthcare, and Centene.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Centene with a $89.36 average price target, a 14.10% upside from current levels. In a report released on February 29, Jefferies also maintained a Buy rating on the stock with a $94.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Centene’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $39.46 billion and a net profit of $45 million. In comparison, last year the company earned a revenue of $35.56 billion and had a GAAP net loss of $213 million
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CNC in relation to earlier this year. Last month, Lori Jean Robinson, a Director at CNC sold 10,000.00 shares for a total of $774,100.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Centene (CNC) Company Description:
Centene Corporation is a diversified healthcare company that primarily engages in providing programs and services to the government sponsored healthcare programs. The company is also engaged in providing education and outreach programs to assist members in accessing quality and appropriate healthcare services.
Read More on CNC:
